文献速递神经肿瘤

CDKN2A/B半合子缺失在IDH突变型胶质瘤中的预后影响

The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma.
PubMed 文献 · Neuro Oncol · 2025-01-01

本研究从海德堡神经病理研究所档案收集334例IDH突变型星形细胞瘤和少突胶质细胞瘤(CNS WHO 2级和3级),通过DNA甲基化分析评估CDKN2A/B半合子缺失与生存的关系。结果显示半合子缺失在星形细胞瘤(37/173)和少突胶质细胞瘤(15/161)中均未显著恶化生存。

要点

  • 星形细胞瘤中CDKN2A/B半合子缺失37/173例,与野生型相比生存无显著差异(log-rank P=0.2556)。
  • 少突胶质细胞瘤中半合子缺失15/161例,与野生型相比生存无显著差异(log-rank P=0.2760)。
  • IDH突变型星形细胞瘤CNS WHO 4级亚组中半合子缺失亦未显著影响生存(log-rank P=0.1680)。

核心结论

  • CDKN2A/B半合子缺失在IDH突变型星形细胞瘤和少突胶质细胞瘤(CNS WHO 2级和3级)中未显著恶化总生存或无进展生存。

研究设计与样本

  • 从海德堡神经病理研究所档案收集诊断为星形细胞瘤IDH突变型和少突胶质细胞瘤IDH突变型1p/19q共缺失CNS WHO 2级和3级的组织样本,共334例低级别胶质瘤,包括173例星形细胞瘤和161例少突胶质细胞瘤。
  • 对福尔马林固定石蜡包埋样本进行DNA甲基化分析,通过视觉检查每个病例甲基化阵列数据衍生的拷贝数图评估CDKN2A/B位点。
  • 半合子缺失和纯合缺失与全染色体或较大节段性丢失和获得一并评估,生存概率采用Kaplan-Meier法评估。

主要发现

  • 星形细胞瘤中CDKN2A/B半合子缺失37/173例,与野生型相比生存无显著差异(log-rank P=0.2556;HR 2.29,95%CI [0.76; 6.40],P=0.135)。
  • 少突胶质细胞瘤中半合子缺失15/161例,与野生型相比生存无显著差异(log-rank P=0.2760;HR 0.17,95%CI [0.01; 5.05],P=0.305)。
  • 星形细胞瘤IDH突变型CNS WHO 4级亚组中半合子缺失亦未显著影响生存(log-rank P=0.1680;HR 4.55,95%CI [0.88; 24.51],P=0.0689)。
  • 半合子缺失对生存的影响不受CNS WHO级别影响。

关键数值与推荐

  • CDKN2A/B半合子缺失在星形细胞瘤中37/173例,在少突胶质细胞瘤中15/161例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Homozygous deletions of CDKN2A/B are known to predict poor prognosis in gliomas, but the impact of hemizygous deletions is less clear. This study aimed to evaluate the prognostic significance of hemizygous CDKN2A/B deletions in IDH-mutant low-grade astrocytomas and oligodendrogliomas. METHODS: Tissue samples diagnosed as astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant, 1p/19q co-deleted CNS WHO grade 2 and 3 were collected from the archives of the Institute of Neuropathology in Heidelberg. DNA methylation analysis was performed on formalin-fixed paraffin-embedded samples. Evaluation of the CDKN2A/B locus was performed by visual inspection of copy-number plots derived from methylation-array data for each case. Hemizygous and homozygous losses were assessed in relation to whole chromosomal or larger segmental losses and gains in the chromosomal profile. Survival probabilities were assessed using the Kaplan-Meier method. RESULTS: A total of 334 low-grade glioma cases were identified, including 173 astrocytomas and 161 oligodendrogliomas. Hemizygous deletions in CDKN2A/B (37/173 in astrocytomas, 15/161 in oligodendrogliomas) did not confer significantly worse survival outcomes compared to CDKN2A/B wild-type cases in neither low-grade astrocytoma (log-rank P = .2556; HR 2.29, 95% CI [0.76; 6.40], P = .135) nor oligodendroglioma (log-rank P = .2760; HR 0.17; 95% CI [0.01; 5.05]; P = .305), regardless of CNS WHO grade, which was further demonstrated on a subgroup of astrocytoma, IDH mutant CNS WHO 4 cases (log-rank P = .1680; HR 4.55, 95% CI [0.88; 24.51], P = .0689). CONCLUSIONS: Hemizygous CDKN2A/B deletions do not significantly worsen OS or progression-free survival in IDH-mutant astrocytomas and oligodendrogliomas, CNS WHO grades 2 and 3.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ippen FM, Hielscher T, Friedel D, et al. The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma. Neuro Oncol. 2025. PMID: 39530475. doi:10.1093/neuonc/noae238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。